Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Michael Shishov is active.

Publication


Featured researches published by Michael Shishov.


Arthritis Care and Research | 2012

Consensus treatments for moderate juvenile dermatomyositis: Beyond the first two months. Results of the Second Childhood Arthritis and Rheumatology Research Alliance Consensus Conference

Adam M. Huber; Angela Byun Robinson; Ann M. Reed; Leslie Abramson; Sharon Bout-Tabaku; Ruy Carrasco; Megan L. Curran; Brian M. Feldman; Harry L. Gewanter; Thomas A. Griffin; Kathleen A. Haines; Mark F. Hoeltzel; Josephine Isgro; Philip Kahn; Bianca Lang; Patti Lawler; Bracha Shaham; Heinrike Schmeling; Rosie Scuccimarri; Michael Shishov; Elizabeth Stringer; Julie Wohrley; Norman T. Ilowite; Carol A. Wallace

To use consensus methods and the considerable expertise contained within the Childhood Arthritis and Rheumatology Research Alliance (CARRA) organization to extend the 3 previously developed treatment plans for moderate juvenile dermatomyositis (DM) to span the full course of treatment.


Arthritis Care and Research | 2015

Novel Method to Collect Medication Adverse Events in Juvenile Arthritis: Results From the Childhood Arthritis and Rheumatology Research Alliance Enhanced Drug Safety Surveillance Project

Sarah Ringold; Audrey Hendrickson; Leslie Abramson; Timothy Beukelman; Peter R. Blier; John F. Bohnsack; Elizabeth C. Chalom; Harry L. Gewanter; Beth S. Gottlieb; Roger Hollister; Joyce Hsu; Andrea Hudgins; Norman T. Ilowite; Marisa S. Klein-Gitelman; Carol B. Lindsley; Jorge M. Lopez Benitez; Daniel J. Lovell; Thomas Mason; Diana Milojevic; Lakshmi N. Moorthy; Kabita Nanda; Karen Onel; Sampath Prahalad; C. Egla Rabinovich; Linda Ray; Kelly Rouster-Stevens; Natasha M. Ruth; Michael Shishov; Steven J. Spalding; Reema H. Syed

Few data are available regarding the rates of serious adverse events (SAEs) and important medical events (IMEs) outside of product‐based registries and clinical trials for juvenile idiopathic arthritis (JIA). The Enhanced Drug Safety Surveillance Project (EDSSP) was developed to pilot a novel system to collect SAEs/IMEs in children with JIA. This analysis reports the results from this 4‐year (2008–2012) EDSSP.


Arthritis & Rheumatism | 2018

Risk, Timing, and Predictors of Disease Flare After Discontinuation of Anti-Tumor Necrosis Factor Therapy in Children With Polyarticular Forms of Juvenile Idiopathic Arthritis With Clinically Inactive Disease

Daniel J. Lovell; Anne Johnson; Bin Huang; Beth S. Gottlieb; Paula W. Morris; Yukiko Kimura; Karen Onel; Suzanne C. Li; Alexei A. Grom; Janalee Taylor; Hermine I. Brunner; Jennifer L. Huggins; James J. Nocton; Kathleen A. Haines; Barbara Edelheit; Michael Shishov; Lawrence K. Jung; Calvin B. Williams; Melissa S Tesher; Denise M. Costanzo; Lawrence S. Zemel; Jason A. Dare; Murray H. Passo; Kaleo Ede; Judyann C. Olson; Elaine Cassidy; Thomas A. Griffin; Linda Wagner-Weiner; Jennifer E. Weiss; Larry B. Vogler

To determine the frequency, time to flare, and predictors of disease flare upon withdrawal of anti–tumor necrosis factor (anti‐TNF) therapy in children with polyarticular forms of juvenile idiopathic arthritis (JIA) who demonstrated ≥6 months of continuous clinically inactive disease.


Arthritis & Rheumatism | 2014

A12: The Role of Serum S100A12 Protein Levels in Disease Flare After Withdrawal of Anti‐tumor Necrosis Factor Therapy in Polyarticular Forms of Juvenile Idiopathic Arthritis

Claas Hinze; Dirk Foell; Anne Johnson; Yukiko Kimura; Steven J. Spalding; Paula W. Morris; Beth S. Gottlieb; Karen Onel; Judyann C. Olson; Barbara Edelheit; Michael Shishov; Lawrence Jung; Elaine Cassidy; Sampath Prahalad; Murray H. Passo; Timothy Beukelman; Jay Mehta; Kara M. Schmidt; Edward H. Giannini; Daniel J. Lovell

Anti‐TNF therapy for polyarticular forms (extended oligo‐, rheumatoid factor +/− polyarthritis) of JIA (PF‐JIA) results in up to 50% of patients (pts) demonstrating clinically inactive disease (CID). This study determined the pattern of serum S100A12 levels at the time of withdrawal of anti‐TNF therapy.


Arthritis & Rheumatism | 2018

Serum S100A8/A9 and S100A12 Levels in Children with Polyarticular Forms of Juvenile Idiopathic Arthritis: Relationship to Maintenance of Clinical Inactive Disease During and Flare after Discontinuation of Anti‐TNF Therapy

Claas Hinze; Dirk Foell; Anne Johnson; Steven J. Spalding; Beth S. Gottlieb; Paula W. Morris; Yukiko Kimura; Karen Onel; Suzanne C. Li; Alexei A. Grom; Janalee Taylor; Hermine I. Brunner; Jennifer L. Huggins; James J. Nocton; Kathleen A. Haines; Barbara Edelheit; Michael Shishov; Lawrence K. Jung; Calvin B. Williams; Melissa S Tesher; Denise M. Costanzo; Lawrence S. Zemel; Jason A. Dare; Murray H. Passo; Kaleo Ede; Judyann C. Olson; Elaine Cassidy; Thomas A. Griffin; Linda Wagner-Weiner; Jennifer E. Weiss

To determine the relationship between serum levels of S100A8/A9 and S100A12 and the maintenance of clinically inactive disease during anti–tumor necrosis factor (anti‐TNF) therapy and the occurrence of disease flare following withdrawal of anti‐TNF therapy in patients with polyarticular forms of juvenile idiopathic arthritis (JIA).


Arthritis & Rheumatism | 2018

High Levels of DEK Autoantibodies in Sera of Patients With Polyarticular Juvenile Idiopathic Arthritis and With Early Disease Flares Following Cessation of Anti-Tumor Necrosis Factor Therapy

Nirit Mor-Vaknin; Miguel Rivas; Maureen Legendre; Smriti Mohan; Ye Yuanfan; Theresa Mau; Anne Johnson; Bin Huang; Lili Zhao; Yukiko Kimura; Steven J. Spalding; Paula W. Morris; Beth S. Gottlieb; Karen Onel; Judyann C. Olson; Barbara Edelheit; Michael Shishov; Lawrence K. Jung; Elaine Cassidy; Sampath Prahalad; Murray H. Passo; Timothy Beukelman; Jay Mehta; Edward H. Giannini; Barbara S. Adams; Daniel J. Lovell; David M. Markovitz

The nuclear oncoprotein DEK is an autoantigen associated with juvenile idiopathic arthritis (JIA), especially the oligoarticular subtype. DEK is a secreted chemotactic factor. Abundant levels of DEK and DEK autoantibodies are found in inflamed synovium in JIA. We undertook this study to further characterize the nature of DEK autoantibodies in screening serum samples from 2 different cohorts that consisted mostly of patients with JIA.


Arthritis Care and Research | 2015

Novel Method to Collect Medication Adverse Events in Juvenile Arthritis: Results From the Childhood Arthritis and Rheumatology Research Alliance Enhanced Drug Safety Surveillance Project: Enhanced Drug Safety Surveillance Project

Sarah Ringold; Audrey Hendrickson; Leslie Abramson; Timothy Beukelman; Peter R. Blier; John F. Bohnsack; Elizabeth C. Chalom; Harry L. Gewanter; Beth S. Gottlieb; Roger Hollister; Joyce Hsu; Andrea Hudgins; Norman T. Ilowite; Marisa S. Klein-Gitelman; Carol B. Lindsley; Jorge M. Lopez Benitez; Daniel J. Lovell; Thomas Mason; Diana Milojevic; Lakshmi N. Moorthy; Kabita Nanda; Karen Onel; Sampath Prahalad; C. Egla Rabinovich; Linda Ray; Kelly Rouster-Stevens; Natasha M. Ruth; Michael Shishov; Steven J. Spalding; Reema H. Syed

Few data are available regarding the rates of serious adverse events (SAEs) and important medical events (IMEs) outside of product‐based registries and clinical trials for juvenile idiopathic arthritis (JIA). The Enhanced Drug Safety Surveillance Project (EDSSP) was developed to pilot a novel system to collect SAEs/IMEs in children with JIA. This analysis reports the results from this 4‐year (2008–2012) EDSSP.


Arthritis Care and Research | 2015

Novel method to collect medication adverse events in juvenile arthritis

Sarah Ringold; Audrey Hendrickson; Leslie Abramson; Timothy Beukelman; Peter R. Blier; John F. Bohnsack; Elizabeth C. Chalom; Harry L. Gewanter; Beth S. Gottlieb; Roger Hollister; Joyce Hsu; Andrea Hudgins; Norman T. Ilowite; Marisa S. Klein-Gitelman; Carol B. Lindsley; Jorge M. Lopez Benitez; Daniel J. Lovell; Thomas Mason; Diana Milojevic; Lakshmi N. Moorthy; Kabita Nanda; Karen Onel; Sampath Prahalad; C. Egla Rabinovich; Linda Ray; Kelly Rouster-Stevens; Natasha M. Ruth; Michael Shishov; Steven J. Spalding; Reema H. Syed

Few data are available regarding the rates of serious adverse events (SAEs) and important medical events (IMEs) outside of product‐based registries and clinical trials for juvenile idiopathic arthritis (JIA). The Enhanced Drug Safety Surveillance Project (EDSSP) was developed to pilot a novel system to collect SAEs/IMEs in children with JIA. This analysis reports the results from this 4‐year (2008–2012) EDSSP.


Pediatric Rheumatology | 2014

High levels of DEK autoantibodies may predict early flare following cessation of anti-TNF therapy in juvenile idiopathic arthritis

Nirit Mor-Vaknin; Miguel Rivas; Maureen Legendre; Y Yuanfang; Anne Johnson; Bin Huang; Yuki Kimura; Lili Zhao; Steve Spalding; Paula W. Morris; Beth S. Gottlieb; Karen Onel; Judyann C. Olson; Barbara Edelheit; Michael Shishov; Larry Jung; Elaine Cassidy; Sampath Prahalad; Murray H. Passo; Timothy Beukelman; Jay Mehta; Kara Schmidt; Ed Giannini; Daniel J. Lovell; David M. Markovitz

The nuclear oncoprotein DEK is a biochemically distinct, pro-inflammatory protein that is a chemoattractant for neutrophils and T-cells. High levels of DEK autoantibodies have been found in several autoimmune diseases including juvenile idiopathic arthritis (JIA), but their role in disease pathogenesis is unclear.


Arthritis & Rheumatism | 2014

A44: High Levels of DEK Autoantibodies May Predict Early Flare Following Cessation of Anti-TNF Therapy

Nirit Mor-Vaknin; Miguel Rivas; Maureen Legendre; Cynthia Yuanfan Ye; Anne Johnson; Bin Huang; Lili Zhao; Yuki Kimura; Steven J. Spalding; Paula W. Morris; Beth S. Gottlieb; Karen Onel; Judyann C. Olson; Barbara Edelheit; Michael Shishov; Lawrence K. Jung; Elaine Cassidy; Sampath Prahalad; Murray H. Passo; Timothy Beukelman; Jay Mehta; Kara M. Schmidt; Edward H. Giannini; Daniel J. Lovell; David M. Markovitz

The nuclear oncoprotein DEK is a biochemically distinct protein, modulating heterochromatin integrity, chemoattractant of neutrophils and T‐cells and vital for the formation of neutrophil extracellular traps (NETs). NETs are important for resolution of inflammation suggesting that DEK contributes to the development of autoimmune diseases. High levels of DEK autoantibodies have been found in several autoimmune diseases including juvenile idiopathic arthritis (JIA) but their role in disease pathogenesis is not clear. Since DEK and DEK autoantibodies can contribute to the development of immune complexes and NET formation we suggest that DEK antibody levels can predict flare with the discontinuation of anti‐TNF therapy.

Collaboration


Dive into the Michael Shishov's collaboration.

Top Co-Authors

Avatar

Beth S. Gottlieb

Boston Children's Hospital

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Daniel J. Lovell

Cincinnati Children's Hospital Medical Center

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Anne Johnson

Cincinnati Children's Hospital Medical Center

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Elaine Cassidy

Boston Children's Hospital

View shared research outputs
Top Co-Authors

Avatar

Judyann C. Olson

Medical College of Wisconsin

View shared research outputs
Researchain Logo
Decentralizing Knowledge